Danaparoid and aspartate aminotransferase increased Patient Reports February 13, 2012

Danaparoid Side Effects Report #5061700-6
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 10, 2006. Female patient, 88 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, blood potassium decreased, blood urea increased, c-reactive protein increased, fibrin d dimer increased, platelet count decreased, prothrombin time prolonged. Danaparoid dosage: unknown. During the same period patient was treated with POLYGLOBIN, PRIMAXIN, DOPAMINE, FLOMOXEF. Patient recovered.

Danaparoid Side Effects Report #5022100-8
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on May 23, 2006. Female patient, 88 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, blood potassium decreased, blood urea increased, c-reactive protein increased, fibrin d dimer increased, prothrombin time prolonged, thrombocytopenia. Danaparoid dosage: unknown. During the same period patient was treated with POLYGLOBIN, PRIMAXIN, DOPAMINE, FLOMOXEF. Patient recovered.

Danaparoid Side Effects Report #5108484-0
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Aug 18, 2006. Female patient, 78 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, condition aggravated, gastrointestinal haemorrhage, haematocrit decreased, haemoglobin decreased, multi-organ failure, red blood cell count decreased, sepsis . Danaparoid dosage: unknown. During the same period patient was treated with MEROPENEM TRIHYDRATE, FAMOTIDINE, CLINDAMYCIN PHOSPHATE, PAZUFLOXACIN, HYDROCORTISONE SUCCINATE, MICAFUNGIN, GABEXATE MESILATE, CARPERITIDE. Patient was hospitalized. Patient died.

Danaparoid Side Effects Report #5113496-7
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 05, 2006. Male patient, 75 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, blood lactate dehydrogenase increased, hepatic function abnormal, shock haemorrhagic, wound infection. Danaparoid dosage: unknown. During the same period patient was treated with ANTITHROMBIN III, CEFAZOLIN, AMIKACIN SULPHATE, SACCHARATED IRON OXIDE. Patient was hospitalized. Patient recovered.


Danaparoid Side Effects Report #4708472-X
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on June 28, 2005. Male patient, 72 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, pancreatitis, white blood cell count increased. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, LEVOTHYROXINE, FERROUS FUMARATE, URSODEOXYCHOLIC ACID, GLYCYRRHIZIC ACID, GLUTATHIONE, VANCOMYCIN, FUROSEMIDE. Patient recovered.

Danaparoid Side Effects Report #5113495-5
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 13, 2006. Female patient, 68 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time shortened, aspartate aminotransferase increased, blood alkaline phosphatase increased, condition aggravated, deep vein thrombosis , international normalised ratio increased, lymphocyte percentage decreased, neutrophil percentage increased, platelet count decreased. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, ANTITHROMBIN III, DOPAMINE, CARBENIN, CLINDAMYCIN PHOSPHATE, ACYCLOVIR, INSULIN, FLUCONAZOLE. Patient recovered.

Danaparoid Side Effects Report #4985074-1
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Aug 25, 2005. Female patient, 66 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, cardiac tamponade, gamma-glutamyltransferase increased, haematocrit decreased, haemoglobin decreased, white blood cell count increased. Danaparoid dosage: unknown. During the same period patient was treated with GLYCEOL, CEFPIROME SULPHATE, EDARAVONE. Patient died.

Danaparoid Side Effects Report #5062431-9
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 07, 2006. Male patient, 58 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, aspartate aminotransferase increased, blood albumin decreased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood potassium decreased, blood urea increased, fibrin d dimer increased. Danaparoid dosage: unknown. During the same period patient was treated with TRANEXAMIC ACID, DAUNOMYCIN, CYTARABINE, ANTITHROMBIN III, MINOPHAGEN C, CEFTAZIDIME. Patient recovered.

Danaparoid Side Effects Report #5116968-4
Danaparoid side effect was reported by a Health Professional from JAPAN on Sept 13, 2006. Female patient, 49 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, ANTITHROMBIN III, MINOCYCLINE HYDROCHLORIDE, CILASTATIN W, OMEPRAZOLE, NAFAMOSTAT MESILATE, SIVELESTAT, DOPAMINE. Patient died.


Danaparoid Side Effects Report #5153402-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Oct 30, 2006. Female patient, 49 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, condition aggravated, gamma-glutamyltransferase increased, hepatic function abnormal, liver disorder. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, ANTITHROMBIN III, MINOCYCLINE, CILASTATIN W, OMEPRAZOLE, NAFAMOSTAT MESILATE, SIVELESTAT, DOPAMINE. Patient was hospitalized. Patient died.

Danaparoid Side Effects Report #5123364-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 05, 2006. Male patient, 40 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: aspartate aminotransferase increased, blood lactate dehydrogenase increased, condition aggravated, disease progression, disseminated intravascular coagulation, hepatic function abnormal, platelet count increased, protein total decreased, renal impairment. Danaparoid dosage: unknown. During the same period patient was treated with AMPICILLIN, IMMUNE GLOBULIN INTRAVENOUS, GABEXATE MESILATE, ANTITHROMBIN III, ULINASTATIN, HAPTOGLOBIN. Patient died.